# Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

> **NCT04568902** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** H3B-6545
- **DRUG:** Antihistamine

## Key facts

- **NCT ID:** NCT04568902
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-30
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04568902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04568902, "Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04568902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*